In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Business Strategies Companies Commercial

MeMed’s Mission: Pressing Its Fingerprint Against AMR

  • Interviews

Executive Summary

Approved in Europe and just given the US green light, MeMed is making waves in the fight against antimicrobial resistance using advanced "host response" technology. Its CEO talks to In Vivo about strategy, commercialization and earning the right to fantasize.

You may also be interested in...



Paragraf Is Finding A Way To Bring Graphene To Diagnostics

The UK-based company is creating a range of diagnostic sensors built using graphene, allowing for faster, more sensitive testing products.

Finding A Way To Bring Graphene To Diagnostics

UK-based Paragraf is working on a range of diagnostic sensors built using graphene, allowing for faster, more sensitive testing products.

MeMed Secures $93M Financing To Commercialize Diagnostics Platform

The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.

Table

View full table

Related Content

In Vivo

Topics

Related Companies

Tags:
Business Strategies Companies Commercial
Latest Headlines

The Serious Business Of Digital Medical Games

Panthera On The SMO Model, Responsible Growth Priorities And The Hybridized Trial Of The Future

New Deals, Modalities In Sights In Japan After Relatively Quiet 2022

The E in ESG: Medtechs Are Getting To Grips With The ‘True Purpose’ Of Carbon Zero

See All
UsernamePublicRestriction

Register

IV124876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By